B. Kurt Copper

Jun 25, 2024 | jdsupra.com | B. Kurt Copper |Antonio F. Dias |António Gomes Dias |Antônio M. Dias |Christopher Domingo

Disputes involving businesses in Texas are changing. Newly formed business courts will open their doors on September 1, 2024, and will have jurisdiction over not only commercial disputes, but also: (i) litigation brought by or against the State of Texas; and (ii) constitutional challenges to state statutes.

Jun 25, 2024 | mondaq.com | Antonio F. Dias |Stephanie Parker |B. Kurt Copper |Christopher Domingo

On June 11, 2024, Governor Greg Abbott appointed the three inaugural justices for the new Fifteenth Court of Appeals, which will hear appeals from business courts statewide. Disputes involving businesses in Texas are changing. Newly formed business courts will open their doors on September 1, 2024, and will have jurisdiction over not only commercial disputes, but also: (i) litigation brought by or against the State of Texas; and (ii) constitutional challenges to state statutes.

Jun 18, 2024 | jdsupra.com | Eric Tung |B. Kurt Copper |Marielle Coutrix |Mary Hickey

In February 2024, the Department of Justice (“DOJ”) announced the results of its 2023 False Claims Act (“FCA”) enforcement efforts. Through those efforts, it obtained more than $2.6 billion in overall recoveries, and of that amount, $1.8 billion came from health care and life sciences (“HCLS”) stakeholders alone. Please see full publication below for more information.

Jun 17, 2024 | lexology.com | Antonio F. Dias |Stephanie Parker |B. Kurt Copper |Christopher Domingo |Matthew A. Kairis |Albert J. Rota

On June 11, 2024, Governor Greg Abbott appointed the three inaugural justices for the new Fifteenth Court of Appeals, which will hear appeals from business courts statewide. Disputes involving businesses in Texas are changing. Newly formed business courts will open their doors on September 1, 2024, and will have jurisdiction over not only commercial disputes, but also: (i) litigation brought by or against the State of Texas; and (ii) constitutional challenges to state statutes.

Sep 1, 2023 | mondaq.com | Heather O'Shea |Claire Castles |B. Kurt Copper |Colleen Heisey

Stakeholders prepare for the U.S. Food and Drug Administration's ("FDA") rulemaking effort to "make explicit" that laboratory developed tests ("LDTs") are devices subject to the agency's oversight, reigniting outstanding questions of jurisdiction and authority. The Office of Management and Budget's Office of Information and Regulatory Affairs ("OIRA") recently received a proposed rulemaking from FDA to regulate LDTs as medical devices under the Federal Food, Drug, and Cosmetic Act ("FDCA").